Evidence map›Paper›PMID 36066840›Full record

ReviewNetherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation2023

Implantable defibrillator therapy and mortality in patients with non-ischaemic dilated cardiomyopathy : An updated meta-analysis and effect on Dutch clinical practice by the Task Force of the Dutch Society of Cardiology.

D A Theuns, T E Verstraelen, A C J van der Lingen, P P Delnoy, C P Allaart, L van Erven, A H Maass, K Vernooy, A A M Wilde, E Boersma and 1 more

Open access · diamondAbstract readReview
In one paragraph

Review in Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Prognostic value of late gadolinium enhancement cardiac MRI for ICD therapy in non-ischaemic cardiomyopathy : A 5-year cohort study.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2025
    Article
  3. Article
  4. 2021 European Society of Cardiology guidelines on cardiac pacing and cardiac resynchronisation therapy : Statement of endorsement by the NVVC.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2025
    Review
  5. Article
  6. Assessment of ICD eligibility in non-ischaemic cardiomyopathy patients: a position statement by the Task Force of the Dutch Society of Cardiology.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2024
    Review
  7. Article
  8. Implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy: a need or not?Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

D A TheunsDepartment of Cardiology, Erasmus MC, Rotterdam, The Netherlands. d.theuns@erasmusmc.nl.
T E VerstraelenAmsterdam UMC, AMC, Amsterdam, The Netherlands.
A C J van der LingenAmsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
P P DelnoyIsala klinieken, Zwolle, The Netherlands.
C P AllaartAmsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
L van ErvenLUMC, Leiden, The Netherlands.
A H MaassUMCG, Groningen, The Netherlands.
K VernooyMaastricht University Medical Center (MUMC+), Maastricht, The Netherlands.
A A M WildeAmsterdam UMC, AMC, Amsterdam, The Netherlands.
E BoersmaDepartment of Cardiology, Erasmus MC, Rotterdam, The Netherlands.
J G MeederVieCuri, Venlo, The Netherlands.
Amsterdam University Medical Centers · NLErasmus University Rotterdam · NLDialyse Centrum Groningen · NLIsala · NLMaastricht University · NLVieCuri Medisch Centrum · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary prophylactic implantable cardioverter-defibrillators (ICDs) in patients with non-ischaemic cardiomyopathy (NICMP) remains controversial. This study sought to assess the benefit of ICD therapy with or without cardiac resynchronisation therapy (CRT) in patients with NICMP. In addition, data were compared with real-world clinical data to perform a risk/benefit analysis.

methodsRelevant randomised clinical trials (RCTs) published in meta-analyses since DANISH, and in PubMed, EMBASE and Cochrane databases from 2016 to 2020 were identified. The benefit of ICD therapy stratified by CRT use was assessed using random effects meta-analysis techniques.

resultsSix RCTs were included in the meta-analysis. Among patients without CRT, ICD use was associated with a 24% reduction in mortality (hazard ratio [HR]: 0.76; 95% confidence interval [CI]: 0.62-0.93; P = 0.008). In contrast, among patients with CRT, a CRT-defibrillator was not associated with reduced mortality (HR: 0.74, 95% CI 0.47-1.16; P = 0.19). For ICD therapy without CRT, absolute risk reduction at 3‑years follow-up was 3.7% yielding a number needed to treat of 27.

conclusionICD use significantly improved survival among patients with NICMP who are not eligible for CRT. Considering CRT, the addition of defibrillator therapy was not significantly associated with mortality benefit compared with CRT pacemaker.

Indexed as

Cardiac resynchronisation therapyImplantable cardioverter-defibrillatorMeta-analysisMortalityNon-ischaemic cardiomyopathySystematic review

Identifiers

PMID36066840
PMCPMC9950314
OpenAlexW4294761413

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.